Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
6(60%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
6
60%
Ph phase_1
1
10%
Ph not_applicable
1
10%
Ph phase_3
1
10%

Phase Distribution

1

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
6(66.7%)
Phase 3Large-scale testing
1(11.1%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

10

all time

Status Distribution
Active(7)
Completed(1)
Other(2)

Detailed Status

Recruiting5
unknown2
Not yet recruiting1
Completed1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
6
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (11.1%)
Phase 26 (66.7%)
Phase 31 (11.1%)
N/A1 (11.1%)

Trials by Status

unknown220%
recruiting550%
not_yet_recruiting110%
completed110%
active_not_recruiting110%

Recent Activity

6 active trials
Showing 5 of 10
recruitingphase_2

Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)

NCT07293468
active_not_recruitingphase_3

A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev

NCT04649489
recruitingphase_2

Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab

NCT07276100
completednot_applicable

The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study

NCT07272265
recruitingphase_2

Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab

NCT07192185
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07293468Phase 2

Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)

Recruiting
NCT04649489Phase 3

A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev

Active Not Recruiting
NCT07276100Phase 2

Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab

Recruiting
NCT07272265Not Applicable

The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study

Completed
NCT07192185Phase 2

Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab

Recruiting
NCT05690048Phase 2

Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)

Recruiting
NCT06971237

SIRT and Peri-immunotherapy : a New Concept

Not Yet Recruiting
NCT06725121Phase 1

Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant

Recruiting
NCT03654833Phase 2

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma

Unknown
NCT04739202Phase 2

Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)

Unknown

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10